On Dec. 10, 2020, Pfizer and BioNTech announced that the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted (17 to 4) in support of the FDA granting Emergency Use Authorization (EUA) for the companiesﾒ COVID-19 mRNA vaccine (BNT162b2). There is one member of the Committee whose vote was not included in the 17 to 4 vote decision.